ClinicalTrials.gg
CompletedNCT03639883Updated Nov 4, 2026

A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision

A Phase 1 interventional study of AIV001 in Scar, Incision and Abdominal, sponsored by AiViva BioPharma, Inc.. Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AiViva BioPharma, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Design changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.

Enrollment
123rd of 185
16 · median 25
Started
2018
with 8 others
Phase 1
13 of 199
1 open now
Registered
123rd of 199
by date

Among the 199 studies in Cicatrix with a site in United States, this one is the 123rd largest by enrollment of the 185 interventional ones that give a count, is one of 9 that started in 2018, is one of 13 in phase 1, and was the 123rd registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Cicatrix with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety, efficacy and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with incisional wounds

Read the detailed description

This is primarily a safety study to evaluate the safety of AIV001 when administered near incisional wounds. A unique model was used to assess incisional scarring, safety and biomarker assessments. Women electing to have the abdominoplasty procedure were enrolled in the study and abdominal incisions were generated on the abdominal skin. Up to 10 incisions were made on abdominal skn and treated as assigned. And data collection was conducted up to day 49 when the subjects were exited from the study and the abdominoplasty procedure performed. Exploratory efficacy measures were collected and pharmacokinetic profiles determined.

03

Conditions studied

  • Scar
  • Incision
  • Abdominal
  • Wound (Morphologic Abnormality)

Keywords

  • wound healing
  • Scar
  • abdominoplasty
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for an abdominoplasty
  • Nonsmoker
  • Fitzpatrick I-IV
  • Weight >45Kg
  • \<= 35

Exclusion criteria

Exclusion Criteria:

  • Existing scars in study area, active infection
  • Any medical history or present conditions that may increase the risk associated with study participation or product administration and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    0.033% versus Vehicle

    One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.

    Drug: AIV001

  • Experimental
    0.1% versus Vehicle

    One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.

    Drug: AIV001

  • Experimental
    0.3% versus Vehicle

    One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.

    Drug: AIV001

  • Experimental
    1% versus Vehicle

    One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.

    Drug: AIV001

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Local and systemic adverse events

    Time frame: Day 1 through Day 49

Secondary outcomes

  1. Efficacy using Patient and Observer Scar Assessment Scale (6 parameters, 1 normal to 10 worst imaginable)

    Evaluation of the healing of the wounds

    Time frame: Day 7 through 49

  2. Modified Vancouver Scar Scale (4 parameters, 0 = normal to 3 or 4 = severe)

    Evaluation of the healing wounds

    Time frame: Day 7 through 49

  3. 100 mm Visual Analogue Scale (0 = normal to 10 = poor scar)

    Evaluation of healing wounds

    Time frame: Day 7 through 49

07

Study locations

2 sites
  • Kaufman and Davis Plastic Surgery
    Folsom, California 95630, United States
  • Cosmetic Laser Dermatology
    San Diego, California 92121, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2019, 12 months.

Of 16 phase 1 interventional studies under Cicatrix, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 17. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 21, 2018
StartActual
Nov 5, 2018
Primary completionActual
Dec 4, 2019
CompletionActual
Dec 19, 2019
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Design
Removed Phase 2
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Design Removed Phase 2
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03639883
Lead sponsor
AiViva BioPharma, Inc.
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Nov 5, 2018
Primary completion
Dec 4, 2019
Completion
Dec 19, 2019
Last update
Nov 4, 2026

Study contacts

James Milbauer, MD
study director · Novella Clinical

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Multi-kinase Inhbitor AIV001

Start the discussion